Professor Amit Nathwani’s journey to create a one-shot cure for haemophilia A
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Professor Amit Nathwani’s journey to create a one-shot cure for haemophilia A
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
To mark World Haemophilia Day, we sit down with Professor Amit Nathwani of the UCL Cancer Institute to explore his journey to commercialising the groundbreaking haemophilia A treatment, Roctavian. Host Nigel Campbell is joined by Prof Nathwani and Dr. Rick Fagan, UCLB Director of Biopharm, to explore how Amit’s work looking after patients with haemophilia in the NHS instilled a mission to develop a 'one and done' vaccine type approach to the condition. Amit’s lab to market story, working with UCLB, led to the creation of Roctavian, a one-time gene therapy used for the treatment of adults with severe haemophilia A. The therapy, which was licensed to BioMarin Pharmaceutical Inc, received marketing approval in Europe in 2022 and US FDA approval in 2023, and is now available to patients commercially.
Date of episode recording: 2024-04-10T00:00:00Z
Duration: 00:23:58
Language of episode: English
Presenter: Nigel Campbell
Guests: Prof Amit Nathwani; Dr Rick Fagan
Producer: Nora Amin
Visit out website for the transcript: https://www.uclb.com/